

Supplementary Figure 1. TBX3 promotes proliferation and migration of liposarcoma cells. A. Western blots confirming successful TBX3 knockdown in SW872 cells after treatment with siTBX3 for 72 h, with p38 as a loading control. B. Knockdown of TBX3 inhibits cell proliferation of SW872 cells. Growth curve assays were performed over a 3-day period and cells harvested by trypsinisation and counted on a haemocytometer. C. Knockdown of TBX3 inhibits cell migration of SW872 cells. 2D-Scratch motility assays were performed and migration was measured at 6-24 h intervals. Two-way ANOVA was used to compare between groups, and data are the mean ± SEM of three independent experiments, ***P<0.001.

Gene Symbol	Gene Name	Cancer Type	Reference
CTSG	cathepsin G	Acute myeloid leukemia	[1]
MYL1	myosin light chain 1	Rhabdomyosarcoma	[2]
PGC	progastricsin	Prostate, ovarian and breast cancer	[3-6]
GKN1	gastrokine 1	Gastric cancer	[7]
LIPF	lipase F, gastric type	Gastric cancer	[8]
TFF2	trefoil factor 2	Colon cancer	[9]
TNNC2	troponin C2	Rhabdomyosarcoma, colon cancer, head and neck squamous cell carcinoma	[10-12]
PIGR	polymeric immunoglobulin receptor	Pancreatic and periampullary cancer	[13]
TFF1	trefoil factor 1	Gastric cancer, pancreatic cancer	[14-17]
MMP12	matrix metallopeptidase 12	Colon, colorectal, gastric, breast and lung cancer, melanoma	[18]
APOA4	apolipoprotein A4	Downregulated in hepatocellular carcinoma and ovarian cancer	[19, 20]
CSN1S1	casein alpha s1	Breast cancer	[21, 22]
CTSE	cathepsin E	Prostate cancer, melanoma	[23]
NCR2	natural cytotoxicity triggering receptor 2	Breast, cervical, colorectal and prostate cancer, melanoma	[24, 25]
CLDN18	claudin 18	Lung adenocarcinoma, gastric cancer	[26, 27]
GKN2	gastrokine 2	Gastric cancer	[28]
AGR2	anterior gradient 2	Lung and pancreatic adenocarcinoma, breast cancer	[29]
SLC26A3	solute carrier family 26 member 3	Colon cancer	[30]
PSCA	prostate stem cell antigen	Esophageal squamous cell carcinoma, prostate cancer, gallbladder cancer	[31-33]
TRPM1	transient receptor potential cation channel subfamily M member 1	Melanoma	[34]

Supplementary Table 1. Overlapping known and predicted tumor suppressor genes

TBX3 and nucleolin co-operate to promote sarcoma proliferation and migration

RPL3L	ribosomal protein L3 like	Endometrial cancer	[35]
REG3A	regenerating family member 3 alpha	Gastric and breast cancer	[36, 37]
ITLN1	intelectin 1	Gastric cancer, neuroblastoma, ovarian cancer	[38-40]
MSMB	microseminoprotein beta	Prostate and ovarian cancer	[41, 42]
TRIM40	tripartite motif containing 40	Gastric and colorectal cancer	[43, 44]
GHRL	ghrelin and obestatin prepropeptide	Gastric and breast cancer	[45, 46]
CLEC1B	C-type lectin domain family 1 member B	Hepatocellular carcinoma	[47]
SERPINB11	serpin family B member 11	Oral squamous cell carcinomas	[48]
SERPINA4	serpin family A member 4	Colorectal, lung, and breast cancer, hepatocellular carcinoma	[49-53]
HAND1	heart and neural crest derivatives expressed 1	Colorectal cancer	[54]
ERN2	endoplasmic reticulum to nucleus signaling 2	Ovarian cancer	[55]
MUC17	mucin 17	Gastric and colorectal cancer	[56, 57]
FAM3D	family with sequence similarity 3 member D	Colon cancer	[58]
CLRN1	clarin 1	Pituitary prolactinoma	[59]
PPP1R3A	protein phosphatase 1 regulatory subunit 3A	Hematological malignancies, non-small cell lung carcinoma	[60, 61]
ANXA10	annexin A10	Prostate, bladder, lung, cervical and cancer, hepatocellular carcinoma	[62-66]
PRLHR	prolactin releasing hormone receptor	Breast cancer	[67]
A4GNT	alpha-1,4-N-acetylglucosaminyltransferase	Gastric cancer	[68]
NR0B2	nuclear receptor subfamily 0 group B member 2	Clear Cell Renal Cell Carcinoma, hepatocellular carcinoma	[69, 70]

Supplementary references

- [1] Jin W, Wu K, Li YZ, Yang WT, Zou B, Zhang F and Wang KK. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia. Oncogene 2013; 32: 1978-87.
- [2] Walters ZS, Villarejo-Balcells B, Olmos D, Buist TW, Missiaglia E, Allen R, Al-Lazikani B, Garrett MD, Blagg J and Shipley J. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene 2014; 33: 1148-57.
- [3] Shen S, Jiang J and Yuang Y. Pepsinogen C expression, regulation and its relationship with cancer. Cancer Cell Int 2017; 17: 57.
- [4] Serra C, Vizoso F, Lamelas ML, Rodríguez JC, González LO, Merino AM, Baltasar A, Pérez-Vázquez MT and Medrano J. Comparative study of two androgen-induced markers (apolipoprotein D and pepsinogen C) in female and male breast carcinoma. Int J Surg Investig 2000; 2: 183-92.
- [5] Serra Díaz C, Vizoso F, Rodríguez JC, Merino AM, González LO, Baltasar A, Pérez-Vázquez MT and Medrano J. Expression of pepsinogen C in gynecomastias and male breast carcinomas. World J Surg 1999; 23: 439-45.
- [6] Rojo JV, Merino AM, González LO and Vizoso F. Expression and clinical significance of pepsinogen C in epithelial ovarian carcinomas. Eur J Obstet Gynecol Reprod Biol 2002; 104: 58-63.
- [7] Yoon JH, Kang YH, Choi YJ, Park IS, Nam SW, Lee JY, Lee YS and Park WS. Gastrokine 1 functions as a tumor suppressor by inhibition of epithelial-mesenchymal transition in gastric cancers. J Cancer Res Clin Oncol 2011; 137: 1697-704.
- [8] Kong Y, Zheng Y, Jia Y, Li P and Wang Y. Decreased LIPF expression is correlated with DGKA and predicts poor outcome of gastric cancer. Oncol Rep 2016; 36: 1852-60.
- [9] Dubeykovskaya Z, Dubeykovskiy A, Worthley DL, Westphalen CB, Asfaha S, Kitur K and Wang TC. Mo2079 Tff2 is a novel tumor suppressor that inhibits expansion of Gr1+CD11b+ myeloid-derived suppressor cells and blocks colon carcinogenesis. Gastroenterology 2012; 143: e25.
- [10] Jin Y and Yang Y. Bioinformatics-based discovery of PYGM and TNNC2 as potential biomarkers of head and neck squamous cell carcinoma. Biosci Rep 2019; 39: BSR20191612.
- [11] Liu Z, Zhang X, Lei H, Lam N, Carter S, Yockey O, Xu M, Mendoza A, Hernandez ER, Wei JS, Khan J, Yohe ME, Shern JF and Thiele CJ. CASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG. Nat Commun 2020; 11: 911.
- [12] Sun Y, Mironova V, Chen Y, Lundh EPF, Zhang Q, Cai Y, Vasiliou V, Zhang Y, Garcia-Milian R, Khan SA and Johnson CH. Molecular pathway analysis indicates a distinct metabolic phenotype in women with right-sided colon cancer. Transl Oncol 2020; 13: 42-56.
- [13] Fristedt R, Elebro J, Gaber A, Jonsson L, Heby M, Yudina Y, Nodin B, Uhlén M, Eberhard J and Jirström K. Reduced expression of the polymeric immunoglobulin receptor in pancreatic and periampullary adenocarcinoma signifies tumour progression and poor prognosis. PLoS One 2014; 9: e112728.

TBX3 and nucleolin co-operate to promote sarcoma proliferation and migration

- [14] Yamaguchi J, Yokoyama Y, Kokuryo T, Ebata T, Enomoto A and Nagino M. Trefoil factor 1 inhibits epithelialmesenchymal transition of pancreatic intraepithelial neoplasm. J Clin Invest 2018; 128: 3619-29.
- [15] Lefebvre O, Chenard MP, Masson R, Linares J, Dierich A, LeMeur M, Wendling C, Tomasetto C, Chambon P and Rio MC. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 1996; 274: 259-62.
- [16] Soutto M, Belkhiri A, Piazuelo MB, Schneider BG, Peng D, Jiang A, Washington MK, Kokoye Y, Crowe SE, Zaika A, Correa P, Peek RM Jr and El-Rifai W. Loss of TFF1 is associated with activation of NF-κB-mediated inflammation and gastric neoplasia in mice and humans. J Clin Invest 2011; 121: 1753-67.
- [17] Heuer J, Heuer F, Stürmer R, Harder S, Schlüter H, Braga Emidio N, Muttenthaler M, Jechorek D, Meyer F and Hoffmann W. The tumor suppressor TFF1 occurs in different forms and interacts with multiple partners in the human gastric mucus barrier: indications for diverse protective functions. Int J Mol Sci 2020; 21: 2508.
- [18] Decock J, Thirkettle S, Wagstaff L and Edwards DR. Matrix metalloproteinases: protective roles in cancer. J Cell Mol Med 2011; 15: 1254-65.
- [19] Bharali D, Banerjee B, Bharadwaj M, Husain S and Kar P. Expression analysis of apolipoproteins AI & AIV in hepatocellular carcinoma: a protein-based hepatocellular carcinoma-associated study. Indian J Med Res 2018; 147: 361.
- [20] Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, Buchner H and Stieber P. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 1127-33.
- [21] Mou MA, Keya NA, Islam M, Hossain MJ, Al Habib MS, Alam R, Rana S, Samad A and Ahammad F. Validation of CSN1S1 transcriptional expression, promoter methylation, and prognostic power in breast cancer using independent datasets. Biochem Biophys Rep 2020; 24: 100867.
- [22] Bonuccelli G, Castello-Cros R, Capozza F, Martinez-Outschoorn UE, Lin Z, Tsirigos A, Xuanmao J, Whitaker-Menezes D, Howell A, Lisanti MP and Sotgia F. The milk protein α-casein functions as a tumor suppressor via activation of STAT1 signaling, effectively preventing breast cancer tumor growth and metastasis. Cell Cycle 2012; 11: 3972-82.
- [23] Kawakubo T, Okamoto K, Iwata J, Shin M, Okamoto Y, Yasukochi A, Nakayama KI, Kadowaki T, Tsukuba T and Yamamoto K. Cathepsin E prevents tumor growth and metastasis by catalyzing the proteolytic release of soluble TRAIL from tumor cell surface. Cancer Res 2007; 67: 10869-78.
- [24] Eisenberg V, Shamalov K, Meir S, Hoogi S, Sarkar R, Pinker S, Markel G, Porgador A and Cohen CJ. Targeting multiple tumors using T-cells engineered to express a natural cytotoxicity receptor 2-based chimeric receptor. Front Immunol 2017; 8: 1212.
- [25] Barrow AD, Edeling MA, Trifonov V, Luo J, Goyal P, Bohl B, Bando JK, Kim AH, Walker J, Andahazy M, Bugatti M, Melocchi L, Vermi W, Fremont DH, Cox S, Cella M, Schmedt C and Colonna M. Natural killer cells control tumor growth by sensing a growth factor. Cell 2018; 172: 534-548, e19.
- [26] Luo J, Chimge NO, Zhou B, Flodby P, Castaldi A, Firth AL, Liu Y, Wang H, Yang C, Marconett CN, Crandall ED, Offringa IA, Frenkel B and Borok Z. CLDN18.1 attenuates malignancy and related signaling pathways of lung adenocarcinoma in vivo and in vitro. Int J Cancer 2018; 143: 3169-80.
- [27] Oshima T, Shan J, Okugawa T, Chen X, Hori K, Tomita T, Fukui H, Watari J and Miwa H. Down-regulation of Claudin-18 is associated with the proliferative and invasive potential of gastric cancer at the invasive front. PLoS One 2013; 8: e74757.
- [28] Ouyang J, Pan X, Lin H, Hu Z, Xiao P and Hu H. GKN2 increases apoptosis, reduces the proliferation and invasion ability of gastric cancer cells through down-regulating the JAK/STAT signaling pathway. Am J Transl Res 2017; 9: 803-11.
- [29] Sommerova L, Ondrouskova E, Vojtesek B and Hrstka R. Suppression of AGR2 in a TGF-β-induced smad regulatory pathway mediates epithelial-mesenchymal transition. BMC Cancer 2017; 17: 546.
- [30] Bhutia YD, Babu E, Ramachandran S, Yang S, Thangaraju M and Ganapathy V. SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms. Biochem J 2016; 473: 1113-24.
- [31] Zhang LY, Wu JL, Qiu HB, Dong SS, Zhu YH, Lee VH, Qin YR, Li Y, Chen J, Liu HB, Bi J, Ma S, Guan XY and Fu L. PSCA acts as a tumor suppressor by facilitating the nuclear translocation of RB1CC1 in esophageal squamous cell carcinoma. Carcinogenesis 2016; 37: 320-32.
- [32] Heinrich MC, Göbel C, Kluth M, Bernreuther C, Sauer C, Schroeder C, Möller-Koop C, Hube-Magg C, Lebok P, Burandt E, Sauter G, Simon R, Huland H, Graefen M, Heinzer H, Schlomm T and Heumann A. PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer. BMC Cancer 2018; 18: 612.
- [33] Ono H, Hiraoka N, Lee YS, Woo SM, Lee WJ, Choi IJ, Saito A, Yanagihara K, Kanai Y, Ohnami S, Chiwaki F, Sasaki H, Sakamoto H, Yoshida T and Saeki N. Prostate stem cell antigen, a presumable organ-dependent tumor suppressor gene, is down-regulated in gallbladder carcinogenesis. Genes Chromosomes Cancer 2012; 51: 30-41.

- [34] Guo H, Carlson JA and Slominski A. Role of TRPM in melanocytes and melanoma. Exp Dermatol 2012; 21: 650-4.
- [35] Takai N, Kawamata N, Walsh CS, Gery S, Desmond JC, Whittaker S, Said JW, Popoviciu LM, Jones PA, Miyakawa I and Koeffler HP. Discovery of epigenetically masked tumor suppressor genes in endometrial cancer. Mol Cancer Res 2005; 3: 261-9.
- [36] Qiu YS, Liao GJ and Jiang NN. REG3A overexpression suppresses gastric cancer cell invasion, proliferation and promotes apoptosis through PI3K/Akt signaling pathway. Int J Mol Med 2018; 41: 3167-3174.
- [37] Zhang P, Zhang J, Yu M, Zhang X and Li H. Over-expression of REG3A gene can inhibit the proliferation, invasion and migration of human breast cancer. Int J Clin Exp Pathol 2016; 9: 12104-13.
- [38] Li D, Zhao X, Xiao Y, Mei H, Pu J, Xiang X, Jiao W, Song H, Qu H, Huang K, Zheng L and Tong Q. Intelectin 1 suppresses tumor progression and is associated with improved survival in gastric cancer. Oncotarget 2015; 6: 16168-82.
- [39] Li D, Mei H, Pu J, Xiang X, Zhao X, Qu H, Huang K, Zheng L and Tong Q. Intelectin 1 suppresses the growth, invasion and metastasis of neuroblastoma cells through up-regulation of N-myc downstream regulated gene 2. Mol Cancer 2015; 14: 47.
- [40] Au-Yeung CL, Yeung TL, Achreja A, Zhao H, Yip KP, Kwan SY, Onstad M, Sheng J, Zhu Y, Baluya DL, Co NN, Rynne-Vidal A, Schmandt R, Anderson ML, Lu KH, Wong STC, Nagrath D and Mok SC. ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment. Nat Commun 2020; 11: 3546.
- [41] Beke L, Nuytten M, Van Eynde A, Beullens M and Bollen M. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 2007; 26: 4590-5.
- [42] Henriksen R, Lundwall Å, Udby L and Fernlund P. The expression of β-microseminoprotein but not CRISP3 is reduced in ovarian cancer and correlates to survival. Anticancer Res 2012; 32: 3993-9.
- [43] Noguchi K, Okumura F, Takahashi N, Kataoka A, Kamiyama T, Todo S and Hatakeyama S. TRIM40 promotes neddylation of IKK and is downregulated in gastrointestinal cancers. Carcinogenesis 2011; 32: 995-1004.
- [44] Eberhardt W, Haeussler K, Nasrullah U and Pfeilschifter J. Multifaceted roles of TRIM proteins in colorectal carcinoma. Int J Mol Sci 2020; 21: 7532.
- [45] Hu XL, Zhu YJ, Hu CH, You L, Wu J, He XY, Huang WJ and Wu ZH. Ghrelin affects gastric cancer progression by activating AMPK signaling pathway. Biochem Genet 2021; 59: 652-67.
- [46] Au CC, Furness JB, Britt K, Oshchepkova S, Ladumor H, Soo KY, Callaghan B, Gerard C, Inghirami G, Mittal V, Wang Y, Huang XY, Spector JA, Andreopoulou E, Zumbo P, Betel D, Dow L and Brown KA. Three-dimensional growth of breast cancer cells potentiates the anti-tumor effects of unacylated ghrelin and AZP-531. Elife 2020; 9: e56913.
- [47] Hu K, Wang ZM, Li JN, Zhang S, Xiao ZF and Tao YM. CLEC1B expression and PD-L1 expression predict clinical outcome in hepatocellular carcinoma with tumor hemorrhage. Transl Oncol 2018; 11: 552-8.
- [48] Shiiba M, Nomura H, Shinozuka K, Saito K, Kouzu Y, Kasamatsu A, Sakamoto Y, Murano A, Ono K, Ogawara K, Uzawa K and Tanzawa H. Down-regulated expression of SERPIN genes located on chromosome 18q21 in oral squamous cell carcinomas. Oncol Rep 2010; 24: 241-9.
- [49] Sun HM, Mi YS, Yu FD, Han Y, Liu XS, Lu S, Zhang Y, Zhao SL, Ye L, Liu TT, Yang DH, Sun XF, Qin XB, Zhou ZG, Tang HM and Peng ZH. SERPINA4 is a novel independent prognostic indicator and a potential therapeutic target for colorectal cancer. Am J Cancer Res 2016; 6: 1636-49.
- [50] Wang NQ, Zou J and Diao Y. Plasmid-mediated expression of kallistatin and its biological activity in lung cancer related cells. Yao Xue Xue Bao 2013; 48: 359-65.
- [51] Shiau AL, Teo ML, Chen SY, Wang CR, Hsieh JL, Chang MY, Chang CJ, Chao J, Chao L, Wu CL and Lee CH. Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin. BMC Cancer 2010; 10: 245.
- [52] Li P, Guo Y, Bledsoe G, Yang Z, Chao L and Chao J. Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis. Exp Cell Res 2016; 340: 305-14.
- [53] Tse LY, Sun X, Jiang H, Dong X, Fung PW, Farzaneh F and Xu R. Adeno-associated virus-mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas. J Gene Med 2008; 10: 508-17.
- [54] Tan J, Yang X, Jiang X, Zhou J, Li Z, Lee PL, Li B, Robson P and Yu Q. Integrative epigenome analysis identifies a Polycomb-targeted differentiation program as a tumor-suppressor event epigenetically inactivated in colorectal cancer. Cell Death Dis 2014; 5: e1324.
- [55] Ow GS, Ivshina AV, Fuentes G and Kuznetsov VA. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures. Cell Cycle 2014; 13: 2262-80.
- [56] Yang B, Wu A, Hu Y, Tao C, Wang JM, Lu Y and Xing R. Mucin 17 inhibits the progression of human gastric cancer by limiting inflammatory responses through a MYH9-p53-RhoA regulatory feedback loop. J Exp Clin Cancer Res 2019; 38: 283.

- [57] Katkoori V, Shanmugam C, Lucas BL, Batra SK, Grizzle WE, Siegal G and Manne U. Abstract #4362: MUC17 is a potential tumor suppressor gene in colorectal adenocarcinoma. Cancer Res 2009; 69.
- [58] Liang W, Peng X, Li Q, Wang P, Lv P, Song Q, She S, Huang S, Chen K, Gong W, Yuan W, Thovarai V, Yoshimura T, O'huigin C, Trinchieri G, Huang J, Lin S, Yao X, Bian X, Kong W, Xi J, Wang JM and Wang Y. FAM3D is essential for colon homeostasis and host defense against inflammation associated carcinogenesis. Nat Commun 2020; 11: 5912.
- [59] Wang C, Tan C, Wen Y, Zhang D, Li G, Chang L, Su J and Wang X. FOXP1-induced IncRNA CLRN1-AS1 acts as a tumor suppressor in pituitary prolactinoma by repressing the autophagy via inactivating Wnt/β-catenin signaling pathway. Cell Death Dis 2019; 10: 499.
- [60] Inoue K, Kohno T, Takakura S, Morishita K, Takita J, Hayashi Y, Mizoguchi H and Yokota J. Alterations of the PPP1R3 gene in hematological malignancies. Int J Oncol 2000; 17: 717-21.
- [61] Kohno T, Takakura S, Yamada T, Okamoto A, Tanaka T and Yokota J. Alterations of the PPP1R3 gene in human cancer. Cancer Res 1999; 59: 4170-4.
- [62] Hung MS, Chen YC, Lin PY, Li YC, Hsu CC, Lung JH, You L, Xu Z, Mao JH, Jablons DM and Yang CT. Cul4A modulates invasion and metastasis of lung cancer through regulation of ANXA10. Cancers (Basel) 2019; 11: 618.
- [63] Miyazawa Y, Sekine Y, Kato H, Furuya Y, Koike H and Suzuki K. Simvastatin up-regulates annexin A10 that can inhibit the proliferation, migration, and invasion in androgen-independent human prostate cancer cells. Prostate 2017; 77: 337-49.
- [64] Munksgaard PP, Mansilla F, Brems Eskildsen AS, Fristrup N, Birkenkamp-Demtröder K, Ulhøi BP, Borre M, Agerbæk M, Hermann GG, Orntoft TF and Dyrskjøt L. Low ANXA10 expression is associated with disease aggressiveness in bladder cancer. Br J Cancer 2011; 105: 1379-87.
- [65] Quiskamp N, Poeter M, Raabe CA, Hohenester UM, König S, Gerke V and Rescher U. The tumor suppressor annexin A10 is a novel component of nuclear paraspeckles. Cell Mol Life Sci 2014; 71: 311-29.
- [66] Peng X, Huang C, Sun Z, Zhang G and Zhu Y. ANXA10 plays a suppressor role by regulating RhoA-ROCK signaling pathway in hepatocellular cancer. Int J Clin Exp Med 2019; 12: 12068-76.
- [67] Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ and Ali S. Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res 2006; 66: 1824-32.
- [68] Karasawa F, Shiota A, Goso Y, Kobayashi M, Sato Y, Masumoto J, Fujiwara M, Yokosawa S, Muraki T, Miyagawa S, Ueda M, Fukuda MN, Fukuda M, Ishihara K and Nakayama J. Essential role of gastric gland mucin in preventing gastric cancer in mice. J Clin Invest 2012; 122: 923-34.
- [69] Zhang Y, Xu P, Park K, Choi Y, Moore DD and Wang L. Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology 2008; 48: 289-98.
- [70] Kudryavtseva AV, Nyushko KM, Zaretsky AR, Shagin DA, Sadritdinova AF, Fedorova MS, Savvateeva MV, Guvatova ZG, Pudova EA, Alekseev BY, Dmitriev AA and Snezhkina AV. Suppression of NR0B2 gene in clear cell renal cell carcinoma is associated with hypermethylation of its promoter. Mol Biol (Mosk) 2018; 52: 482-8.